XML 22 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
STOCKHOLDERS' EQUITY

NOTE 4:- STOCKHOLDERS' EQUITY

 

  a. The Common Stock confers upon their holders the right to participate and vote in general shareholder meetings of the Company and to share in the distribution of dividends, if any, declared by the Company, and rights to receive a distribution of assets upon liquidation.
     
  b. On January 9, 2020, the Company entered into the Bonus Agreements and the Series B Purchase Agreement (as such terms are defined in Note 5 below), whereby, at the closing of both transactions, which occurred on February 19, 2020, (i) the Company sold 37% of future revenues (if any) from its LO2A Proceeds to Bonus, an Israeli company whose ordinary shares are traded on the Tel Aviv Stock Exchange ("TASE"), and invested cash amount of $7,400 in Bonus (of which $3,700 are held in trust) and (ii) in consideration, Bonus issued to the Company new ordinary shares of Bonus in a number equal to $16,400 divided by a purchase price per share of NIS 0.50 (approximately $0.12). The fair value of such Bonus ordinary shares received, based on a quote of the share price on January 9, 2020, the date of signing the Bonus Agreements, was $0.12 and, as of the date of the closing of the transactions, was $0.11.

  

  c. On August 11, 2020, the Company's Board of Directors approved the following equity grants: (i) 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of Directors of the Company and (ii) 100,000 restricted stock units vesting quarterly over a period of two years to each of the other three non-executive directors.